Allison Wildin, DO
Rheumatology · Jefferson City, MONPI 1437569381
Payments from drug & device makers
Across 74 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$164
- Johnson & Johnson$158
- Boehringer Ingelheim$147
- Amgen$116
- AstraZeneca$72
- Baxter Healthcare$61
- plus $599 from 21 others
What the payments were for
- Food & beverage$1,28898%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $164 |
| Johnson & Johnson | 10 | $158 |
| Boehringer Ingelheim | 9 | $147 |
| Amgen | 7 | $116 |
| AstraZeneca | 4 | $72 |
| Baxter Healthcare | 3 | $61 |
| Radius Health, Inc. | 3 | $59 |
| Novartis | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| UCB, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $36 |
| Pfizer | 2 | $33 |
| GSK | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Grifols USA, LLC | 2 | $28 |
| Intercept Pharmaceuticals, Inc. | 2 | $27 |
| ERMI LLC | 1 | $24 |
| Abbott | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Bioventus LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Harmony Biosciences LLC | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $15 |
How this compares
$1,317 in reported general payments places this provider in the 40th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 88 | $694,632 |
| RinvoqUpadacitinib | 54 | $354,548 |
| Humira(Cf)Adalimumab | 27 | $354,492 |
| Orencia ClickjectAbatacept | 50 | $289,222 |
| Enbrel SureclickEtanercept | 25 | $216,160 |
| Cosentyx Sensoready PenSecukinumab | 22 | $187,364 |
| Humira PenAdalimumab | 24 | $177,064 |
| OtezlaApremilast | 33 | $172,261 |
| Xeljanz XrTofacitinib Citrate | 18 | $162,424 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $119,687 |
| EnbrelEtanercept | 13 | $91,991 |
| BenlystaBelimumab | 18 | $85,764 |
| XeljanzTofacitinib Citrate | 11 | $72,808 |
| Hydroxychloroquine Sulfate | 472 | $21,204 |
| Celecoxib | 215 | $14,859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Savella | $164 | $723,426105 claims |
| AmgenOtezla, Enbrel | $116 | $264,25346 claims |
| GSKBenlysta | $30 | $85,76418 claims |
| PfizerXeljanz | $33 | $72,80811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 134 rheumatology providers in Missouri.
Other rheumatology in Jefferson City
- Stephen SidesJefferson City$50K
- John ErvinKansas City$18.7M
- David TrueSpringfield$15.8M
- Ghaith NoaisehKansas City$1.6M
- Anne WinklerCarthage$1.6M
- Alfred KimSaint Louis$1.2M
- Tina ShahKansas City$1.2M
- Sona KamatSaint Louis$931K
- Akgun InceSaint Louis$849K
- Adam KilianSaint Louis$593K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.